{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:12:35Z","timestamp":1788833555795,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.juro.2009.07.046","type":"journal-article","created":{"date-parts":[[2009,9,17]],"date-time":"2009-09-17T09:05:20Z","timestamp":1253178320000},"page":"2257-2264","source":"Crossref","is-referenced-by-count":50,"title":["Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy"],"prefix":"10.1097","volume":"182","author":[{"given":"Nirmala","family":"Bhoopalam","sequence":"first","affiliation":[{"name":"Edward Hines, Jr. Veterans Affairs Hospital, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Edward Hines, Jr. Veterans Affairs Hospital, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Moritz","sequence":"additional","affiliation":[{"name":"Edward Hines, Jr. Veterans Affairs Hospital, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Broderick","sequence":"additional","affiliation":[{"name":"Edward Hines, Jr. Veterans Affairs Hospital, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmini","family":"Iyer","sequence":"additional","affiliation":[{"name":"Veterans Affairs Long Beach Healthcare System, Long Beach, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G.","family":"Arcenas","sequence":"additional","affiliation":[{"name":"Washington, D.C. Veterans Affairs Medical Center, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Van Veldhuizen","sequence":"additional","affiliation":[{"name":"Kansas City Veterans Affairs, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Friedman","sequence":"additional","affiliation":[{"name":"Edward Hines, Jr. Veterans Affairs Hospital, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenic","family":"Reda","sequence":"additional","affiliation":[{"name":"Edward Hines, Jr. Veterans Affairs Hospital, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Warren","sequence":"additional","affiliation":[{"name":"Cooperative Studies Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Garewal","sequence":"additional","affiliation":[{"name":"Southern Arizona Veterans Affairs Healthcare System, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2009.07.046_bib1","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","article-title":"Osteoporosis in men treated with androgen deprivation therapy for prostate cancer","volume":"167","author":"Ross","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.046_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","article-title":"Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens","volume":"57","author":"Eriksson","year":"1995","journal-title":"Calc Tiss Int"},{"key":"10.1016\/j.juro.2009.07.046_bib3","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostate carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.046_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2009.07.046_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.07.046_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.046_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniel","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.046_bib8","first-page":"1521","article-title":"Osteoporosis in men","volume":"67","author":"Campion","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.juro.2009.07.046_bib9","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2009.07.046_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.046_bib11","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2009.07.046_bib12","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.046_bib13","unstructured":"CGP 42446, Zometa\u00ae (Zoledronic Acid) Investigators' Brochure, 1998."},{"key":"10.1016\/j.juro.2009.07.046_bib14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP42\u2032446, a new potent heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Min Res"},{"key":"10.1016\/j.juro.2009.07.046_bib15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing-hormone-agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2009.07.046_bib16","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.07.046_bib17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of post-menopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.07.046_bib18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.juro.2009.07.046_bib19","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.07.046_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/003335490712200113","article-title":"Veterans using and uninsured veterans not using Veterans Affairs (VA) health care","volume":"122","author":"Nelson","year":"2007","journal-title":"Public Health Rep"},{"key":"10.1016\/j.juro.2009.07.046_bib21","unstructured":"Pandya MB, Bhoopalam N, Moritz T et al: A multicenter VA study of zoledronic acid in men on androgen deprivation therapy for prostate cancer with osteoporosis. Presented at Genitourinary Cancers Symposium, San Francisco, California, February 14\u201316, 2008, abstract 251."},{"key":"10.1016\/j.juro.2009.07.046_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jn\/135.2.317","article-title":"Circulating 25-hydroxyvitamin D Levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D","volume":"135","author":"Hollis","year":"2005","journal-title":"J Nutr"},{"key":"10.1016\/j.juro.2009.07.046_bib23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.046_bib24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.juro.2007.09.028","article-title":"Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy","volume":"179","author":"Israeli","year":"2008","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534709017753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534709017753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2009.07.046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:49:40Z","timestamp":1651196980000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2009.07.046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1016\/j.juro.2009.07.046"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2009.07.046","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}